Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy

NCT03463161 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT03463161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03463161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Terminated
Start date
March 23, 2018
Completion date
December 4, 2018
Enrollment
2 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck squamous cell carcinoma